Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, or the “Company”, Nasdaq: OLMA) today announced interim results from an ongoing Phase 1b/2 clinical study of OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), in combination with palbociclib, a CDK4/6 inhibitor, for the treatment of ER+/HER2- metastatic…Read More
Olema Announces OP1250 Continues to Demonstrate Attractive Combinability with CDK46 Inhibitor Palbociclib in Phase 1b2 Study By Investingcom
